Endo Pharmaceuticals Holdings has raised $900 million in a two part sale of senior unsecured notes. Securities worth $500 million, which carry a coupon rate of 7%, are set to mature on July 15, 2019, while notes costing $400 million carrying a coupon of 7.25%, will be due on Jan.15, 2022. The U.S. specialty healthcare solutions company is seeking to use the proceeds from the offering to finance its acquisition of AMS, to refinance its existing credit facility and existing AMS indebtedness. Bank of America Merrill Lynch, Morgan Stanley, Citi and Deutsche Bank were named as joint book-running managers for the deal, adds Reuters.
Click here for the release from Endo Pharmaceuticals.
Click here for additional coverage from Reuters.